Table 1.
Outcomes of prospective clinical trials of first-line treatment regimens in BL.
| Regimen | Histology | N | Age, median (range) | Stage III/IV (or high risk) | CR | EFS/PFS (years) | OS (years) | TRM |
|---|---|---|---|---|---|---|---|---|
| CODOX-M/IVAC[113] | BL | 41 | 17 (3–59) | 80% | 95% | 92% EFS (2) | NR | 3% |
| CODOX-M/IVAC[114] | BL | 52 | 35 (15–60) | 61% | 77% | 65% EFS (2) | 73% (2) | 8% |
| AMC-048[64] a | HIV+ BL | 34 | 42 (19–55) | 74% | NR | 69% PFS (1) | 69% (2) | 3% |
| CODOX-M/IVAC[58] | BL/BL-like | 14 | 47 (18–65) | 64% | 90% | 64% PFS (2) | 71% (2) | 0% |
| R-CODOX-M/IVAC[115] a | BL | 25 | 44 (23–70) | (80%) | 92% | 80% PFS (2) | 84% (2) | 0% |
| Hyper-CVAD[56] | B-ALL | 26 | 58 (17–79) | 100% | 81% | 61% DOR (3) | 49% (3) | 19% |
| R-Hyper-CVAD[57] | BL B-ALL |
31 | 46 (17–77) | NR | 86% | 80% EFS (3) | 89% (3) | 0% |
| LMB89[68] b | BL B-ALL |
561 | 8 (0–18) | 79% | 97% | 91% EFS (5) | 92% (5) | 1% |
| LMB95[69] b | BL | 72 | 33 (18–76) | 67% | 72% | 65% EFS (2) | 70% (2) | 4% |
| LMB±R[53] b | BL | 257 | 47 (IQR 31–59) | 62% | NR | R 75% EFS (3) No R 62% EFS |
R 83% (3) No R 70% |
5% |
| BFM 90[70] b | BL B-ALL |
322 | 9 (1–18) | 60% | NR | 89% EFS (6) | NR | 3% |
| GMALL-B-ALL/NHL 2002[54] b | BL B-ALL |
363 | 42 (16–85) | 71% | 88% | 75% PFS (5) | 80% (5) | 4% |
| Alliance[72] b | BL B-ALL |
105 | 43 (19–79) | 49% | 83% | 78% EFS (2) | 80% (2) | 7% |
| SC-EPOCH-RR[61] | HIV+ BL | 11 | 44 (24–60) | 82% | 91% | 100% FFP (6) | 90% (6) | 0 |
| DA-EPOCH-R[61] | BL | 19 | 25 (15–88) | 58% | 100% | 95% FFP (7) | 100% (7) | 0 |
| DA-EPOCH-R[75] | BL HIV+ BL |
110 29 HIV+ |
49 (18–86) | 69% | NR | 86% PFS (3) | 86% (3) | 5% |
a
includes an optional prephase (corticosteroids +/− cyclophosphamide)
b
includes a mandatory prephase (corticosteroids +/− cyclophosphamide +/− vincristine)
B-ALL: B-cell acute lymphoblastic leukemia; BL: Burkitt lymphoma; DFS: disease-free survival; DOR: duration of remission; EFS: event-free survival; FFP: freedom from progression; IQR: interquartile range; NR: not reported; PFS: progression-free survival; R: rituximab; TRM: treatment-related mortality